January 19, 2011 |
While the overall stroke rate in the United States has declined in the last decade, the rate among people infected with the AIDS virus has climbed sharply, researchers reported Wednesday. Although the reason for the increase is not clear, many experts suspect that it is related to the use of protease inhibitors to control replication of the virus. While the drugs, as part of cocktails of antiretroviral medications, have proved remarkably effective in controlling the virus and prolonging patients' lives, they have also interfered with the patients' lipid metabolism, increasing the levels of cholesterol and lipids in patients' blood and altering the distribution of fats in their bodies.
June 5, 2011 |
Thirty years ago Sunday, a brief report in the Morbidity and Mortality Weekly Report described cases of a rare form of pneumonia called Pneumocystis carinii in five young Los Angeles men, "all active homosexuals. " The cases were noteworthy because the men had previously been healthy, though their particular pneumonia had only been seen in people with severely depressed immune systems. Within a month, a second report had identified 54 young gay men with a rare cancer known as Kaposi's sarcoma, another disease that had been almost unknown in young men. And by the following summer, the mysterious disease underlying these reports had a name: acquired immune deficiency syndrome, or AIDS.
April 15, 1998 |
Agouron Pharmaceuticals Inc. said Tuesday that sales of its HIV drug Viracept totaled $308 million during the drug's first full year on the market, making it the most successful biotechnology drug launch ever. The strong sales at the La Jolla-based biotech firm eclipsed the previous maiden-year record of $240 million that analysts estimate was the revenue generated by Neupogen, a drug introduced in 1991 by Thousand Oaks-based Amgen Inc.
January 23, 1997 |
A leading AIDS researcher on Wednesday raised the provocative notion that powerful drug combinations could eradicate the AIDS virus from the body after three years. Dr. David Ho, the highly respected director of the Aaron Diamond AIDS Research Center in New York, said a mathematical model developed by one of his collaborators projected the three-year period for eliminating the virus from an infected individual receiving a successful drug-combination treatment.
January 30, 1996 |
In some of the strongest evidence thus far that a new generation of AIDS drugs can inhibit the human immunodeficiency virus, scientists reported Monday that HIV became virtually undetectable in most patients six months after starting treatment with one of the new drugs in combination with two standard ones. "For the first time we may be close to achieving almost total suppression of the AIDS virus in most patients," said Dr.
July 4, 1996 |
For the first time since the AIDS epidemic began sweeping across America and the world, physicians think they may have the weapons to place them on an equal footing with the deadly virus. While cautious about using the word "cure," researchers gathering Sunday in Vancouver for the 11th International Conference on AIDS are optimistic that they can begin to bring the epidemic under control.
June 5, 2004
Re "Activists Put Drug Research on Chopping Block," Commentary, June 1: I was described by James Glassman and Nick Schulz as a "left-wing activist" who is engaged in a "relentless campaign against technological innovation" spreading "Luddite nonsense that kills people." Allow me to respond. What has them riled up is Essential Inventions' petition asking the Bush administration to allow generic drug companies to use six government-funded patents relating to the AIDS drug ritonavir, sold now under the trade name Norvir.
June 19, 1997 |
Federal health officials are expected to recommend today that most HIV-infected patients be treated early and aggressively with potent triple-drug combinations that include a protease inhibitor, a regimen that is not always currently practiced among clinicians nationwide.
November 14, 1997 |
Despite the effectiveness of powerful new drug combinations for suppressing infections of the AIDS virus, researchers are reluctantly concluding that the treatments may never be able to eradicate the human immunodeficiency virus from the body. Unless unexpected new treatments are discovered, experts say, those infected with the virus will most likely have to continue taking the expensive drug combinations for the rest of their lives.
November 5, 1996 |
Tom Bianchi, HIV-positive and holding, uses two words to describe the situation in which he finds himself: "Future shock." Seated on the sofa of his Park La Brea townhouse, an arm around his partner of five years, Mark Prunty, Bianchi recalls that three years ago their therapist was "trying to prepare us for my demise. I was right at the 'Oh, my God!' mark." When Bianchi's condition was diagnosed in 1989, getting the AIDS virus was a death sentence.